ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

glumetinib

Also written as “Glumetinib”, “Gumarontinib Tablets” and “Glumetinib Tablets”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageGlumetinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 7, 20198 company-led studies, 4 open or runningNext primary completion: Dec 25, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haihe Biopharmaits history only51 open or runningphase 2since Aug 7, 2019Aug 7, 2017none ahead
CSPC Pharmaceutical Group33 open or runningphase 3since Feb 11, 2025Jul 18, 2024Dec 25, 2026phase 2 · NCT06525350

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2024First study: phase 2 study in RecurrenceFirst studyNCT06525350 · 256 planned
  2. Feb 11, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06829459 · 350 planned · China
  3. Mar 27, 2025Phase 3 study in RecurrenceNCT06908772 · 390 planned

Ahead

  1. Dec 25, 2026Primary completion: phase 2 study in RecurrenceNCT06525350
  2. Feb 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06829459
  3. Dec 31, 2028Primary completion: phase 3 study in RecurrenceNCT06908772

TargetBeta

MET →read by rule
“An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 3 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06908772Recurrence3Not yet recruitingDec 31, 2028390
NCT06829459Carcinoma, Non-Small-Cell Lung · China3RecruitingFeb 15, 2028350
NCT06525350Recurrence2Not yet recruitingDec 25, 2026256

How it is read

Names in the registry

  • “Glumetinib”, 4 entries
  • “Gumarontinib Tablets”, 2 entries
  • “Glumetinib Tablets”, 1 entry
  • “Glumetinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.